Immunomodulation by Soluble Factors from Tumor Cells Cultured in vivo in Diffusion Chambers

Tumor Biology ◽  
1994 ◽  
Vol 15 (3) ◽  
pp. 160-165 ◽  
Author(s):  
Slobodanka Klein ◽  
Maria Adela Jasnis ◽  
Miriam Diament ◽  
Lilia Davel ◽  
Julio Aguirre ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Soluble Factors ◽  
Diffusion Chambers ◽  
Cells Cultured

Molecular Characterization of Gene Expression Changes in ROS 17/2.8 Cells Cultured in Diffusion Chambers In Vivo

1999 ◽  
Vol 65 (2) ◽  
pp. 133-138 ◽  
Author(s):  
J. E. Onyia ◽  
L. V. Hale ◽  
R. R. Miles ◽  
R. L. Cain ◽  
Y. Tu ◽  
...  
Keyword(s):  
Gene Expression ◽  
Molecular Characterization ◽  
Diffusion Chambers ◽  
Cells Cultured

scholarly journals THE IN VIVO REUTILIZATION OF LYMPHOCYTIC AND SARCOMA DNA BY CELLS GROWING IN THE PERITONEAL CAVITY

1962 ◽  
Vol 13 (2) ◽  
pp. 205-216 ◽  
Author(s):  
William O. Rieke
Keyword(s):  
Peritoneal Cavity ◽  
Mononuclear Cells ◽  
Tritiated Thymidine ◽  
Ascites Tumor ◽  
Diffusion Chambers ◽  
Transplanted Tumor ◽  
Tumor Bearing ◽  
Sarcoma Cells ◽  
Cells Cultured

An ascites tumor, Sarcoma I, was transplanted to isologous and homologous mice which had been labeled with tritiated thymidine from 1 to 24 hours previously. Radioautographic preparations revealed labeled host lymphocytes emerging to mingle with the transplanted tumor and the subsequent appearance of nuclear radioactivity in the sarcoma. Sarcoma cells cultured subcutaneously or in Millipore diffusion chambers in previously labeled mice did not demonstrate significant radioactivity. Transplantation of washed, H3-thymidine-labeled lymphocytes to non-radioactive, sarcoma-bearing mice was followed by the gradual appearance of nuclear radioactivity in the sarcoma. The label in the sarcoma was entirely removed by deoxyribonuclease but not by ribonuclease treatment prior to radioautography. Intraperitoneal injections of purified, H3-thymidine-labeled sarcoma or lymphoid DNA in normal or tumor-bearing mice were followed by radioactivity appearing in sarcoma or normal peritoneal mononuclear cells. It was concluded that reutilization of DNA and its metabolites may occur in vivo, and the conditions under which reutilization may be detected are discussed.

In Vivo Inhibition of Antitumor Immunity by Embryonic Antigens

1976 ◽  
Vol 62 (2) ◽  
pp. 211-218 ◽  
Author(s):  
Rosario Lembo ◽  
Giorgio Parmiani
Keyword(s):  
Tumor Cells ◽  
Antitumor Immunity ◽  
Normal Adult ◽  
Embryonic Cells ◽  
Diffusion Chambers ◽  
Embryonic Tissues ◽  
Embryonic Antigens ◽  
Transplantation Antigens ◽  
Adult Cells

Adult female BALB/c mice were immunized against the 3-methylcholanthrene–induced fibrosarcoma ST2 by growth and excision, and then injected with either neoplastic or embryonic mitomycin-C-blocked syngeneic cells before receiving a subcutaneous challenge of 105 ST2 cells. Other groups of similarly immunized females were intraperitoneally implanted with cell-impermeable diffusion chambers containing neoplastic or embryonic tissues, or mated to syngeneic males, before being challenged with ST2 cells. The mice immunized and injected with blocked ST2 but not with embryonic or antigenically unrelated neoplastic cells showed a resistance to the growth of ST2 significantly lower than that of immune mice given normal adult cells. This was particularly evident when ST2 blocked cells were given parenterally but was also detectable when ST2 blocked cells were cultured within diffusion chambers kept in tumor–excised mice. The syngeneic pregnancy had no effect on the antitumor immunity. In a subsequent study, BALB/c females were challenged with the same number of ST2 tumor cells as above, but the challenge was performed at days +4, +2, 0, –-2, –-4 from excision, and the blocked neoplastic embryonic or normal adult cells were given starting at the day of challenge. It was found that when the challenge was done 4 and 2 days after the excision, the administration of either antigenically-related tumor cells or embryonic cells could reduce the antitumor immune protection, while no such an effect was detectable in the other experimental groups. Thus, in addition to tumor-associated transplantation antigens, embryonic antigens also seem to be able to impair the developing antitumor immunity provided they are given within four days from the excision of the immunizing growth.

Recovery of Tumor Cells Cultured in Vivo after X-Ray and Neutron Irradiations

1962 ◽  
Vol 16 (5) ◽  
pp. 712 ◽  
Author(s):  
S. Hornsey ◽  
G. Silini
Keyword(s):  
Tumor Cells ◽  
X Ray ◽  
Cells Cultured

Melatonin modifies tumor hypoxia and metabolism by inhibiting HIF-1α and energy metabolic pathway in the in vitro and in vivo models of breast cancer

2019 ◽  
Vol 2 (4) ◽  
pp. 83-98 ◽  
Author(s):  
André De Lima Mota ◽  
Bruna Vitorasso Jardim-Perassi ◽  
Tialfi Bergamin De Castro ◽  
Jucimara Colombo ◽  
Nathália Martins Sonehara ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Glucose Metabolism ◽  
Tumor Growth ◽  
Tumor Cells ◽  
Carbonic Anhydrases ◽  
In Vivo Models ◽  
Ca Ix ◽  
Gene And Protein Expression

Breast cancer is the most common cancer among women and has a high mortality rate. Adverse conditions in the tumor microenvironment, such as hypoxia and acidosis, may exert selective pressure on the tumor, selecting subpopulations of tumor cells with advantages for survival in this environment. In this context, therapeutic agents that can modify these conditions, and consequently the intratumoral heterogeneity need to be explored. Melatonin, in addition to its physiological effects, exhibits important anti-tumor actions which may associate with modification of hypoxia and Warburg effect. In this study, we have evaluated the action of melatonin on tumor growth and tumor metabolism by different markers of hypoxia and glucose metabolism (HIF-1α, glucose transporters GLUT1 and GLUT3 and carbonic anhydrases CA-IX and CA-XII) in triple negative breast cancer model. In an in vitro study, gene and protein expressions of these markers were evaluated by quantitative real-time PCR and immunocytochemistry, respectively. The effects of melatonin were also tested in a MDA-MB-231 xenograft animal model. Results showed that melatonin treatment reduced the viability of MDA-MB-231 cells and tumor growth in Balb/c nude mice (p <0.05). The treatment significantly decreased HIF-1α gene and protein expression concomitantly with the expression of GLUT1, GLUT3, CA-IX and CA-XII (p <0.05). These results strongly suggest that melatonin down-regulates HIF-1α expression and regulates glucose metabolism in breast tumor cells, therefore, controlling hypoxia and tumor progression. 

ANTITUMOR EFFECT OF COLLOIDAL SILVER BISILICATE IN EXPERIMENTAL IN VITRO AND IN VIVO STUDIES

2019 ◽  
Vol 65 (5) ◽  
pp. 760-765
Author(s):  
Margarita Tyndyk ◽  
Irina Popovich ◽  
A. Malek ◽  
R. Samsonov ◽  
N. Germanov ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Tumor Growth ◽  
Tumor Cells ◽  
Human Tumor ◽  
Significant Inhibition ◽  
In Vivo Studies ◽  
Ehrlich Carcinoma ◽  
In Vivo Experiments

The paper presents the results of the research on the antitumor activity of a new drug - atomic clusters of silver (ACS), the colloidal solution of nanostructured silver bisilicate Ag6Si2O7 with particles size of 1-2 nm in deionized water. In vitro studies to evaluate the effect of various ACS concentrations in human tumor cells cultures (breast cancer, colon carcinoma and prostate cancer) were conducted. The highest antitumor activity of ACS was observed in dilutions from 2.7 mg/l to 5.1 mg/l, resulting in the death of tumor cells in all studied cell cultures. In vivo experiments on transplanted Ehrlich carcinoma model in mice consuming 0.75 mg/kg ACS with drinking water revealed significant inhibition of tumor growth since the 14th day of experiment (maximally by 52% on the 28th day, p < 0.05) in comparison with control. Subcutaneous injections of 2.5 mg/kg ACS inhibited Ehrlich's tumor growth on the 7th and 10th days of the experiment (p < 0.05) as compared to control.

Sign in / Sign up

Export Citation Format

Share Document